Log in
NASDAQ:FATE

Fate Therapeutics Stock Forecast, Price & News

$57.92
+0.79 (+1.38 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$57.06
Now: $57.92
$58.96
50-Day Range
$43.94
MA: $49.19
$57.13
52-Week Range
$13.26
Now: $57.92
$58.96
Volume302,630 shs
Average Volume982,472 shs
Market Capitalization$5.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
Fate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Employees178

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.68 million
Book Value$3.24 per share

Profitability

Net Income$-98,150,000.00
Net Margins-881.86%

Miscellaneous

Market Cap$5.05 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$57.92
+0.79 (+1.38 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

How has Fate Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 143.5% and is now trading at $57.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Fate Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fate Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Fate Therapeutics?

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Fate Therapeutics
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.39. The biopharmaceutical company earned $7.56 million during the quarter, compared to analyst estimates of $7.49 million. Fate Therapeutics had a negative net margin of 881.86% and a negative return on equity of 38.64%. The company's revenue was up 211.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.40) earnings per share.
View Fate Therapeutics' earnings history
.

What price target have analysts set for FATE?

12 brokerages have issued 1 year target prices for Fate Therapeutics' stock. Their forecasts range from $30.00 to $71.00. On average, they expect Fate Therapeutics' share price to reach $50.19 in the next year. This suggests that the stock has a possible downside of 13.4%.
View analysts' price targets for Fate Therapeutics
.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), 1877 (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres & Director (Age 50, Pay $850.5k)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 52, Pay $525.94k)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 47, Pay $525.94k)
  • Dr. Bahram Valamehr Ph.D., Chief Devel. Officer (Age 43, Pay $525.94k)
  • Mr. Edward J. Dulac III, CFO & Principal Accounting Officer (Age 45)
  • Dr. Wen Bo Wang, Sr. VP of Technical Operations
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
  • Dr. Sarah Cooley, Sr. VP of Clinical Translation
  • Dr. Yu-Waye Chu M.D., Sr. VP of Clinical Devel.

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.56%), State Street Corp (3.34%), Victory Capital Management Inc. (2.80%), ARK Investment Management LLC (1.66%), Jennison Associates LLC (1.17%) and Polaris Venture Management Co. V L.L.C. (0.98%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc.
View institutional ownership trends for Fate Therapeutics
.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., State Street Corp, Point72 Asset Management L.P., Victory Capital Management Inc., BNP Paribas Arbitrage SA, Federated Hermes Inc., Squarepoint Ops LLC, and Nikko Asset Management Americas Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko.
View insider buying and selling activity for Fate Therapeutics
.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., ARK Investment Management LLC, Cubist Systematic Strategies LLC, Morgan Stanley, SG Americas Securities LLC, JPMorgan Chase & Co., Segall Bryant & Hamill LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for Fate Therapeutics
.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $57.92.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $5.05 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 178 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.